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Breast cancerEmerging evidences suggest that chronic inﬂammation is one of the major causes of tumorigenesis. The role of
inﬂammation in regulation of breast cancer progression is notwell established. RecentlyMediator of IRF3 Activa-
tion (MITA) protein has been identiﬁed that regulates NF-κB and IFN pathways. Role of MITA in the context of
inﬂammation and cancer progression has not been investigated. In the current report, we studied the role of
MITA in the regulation of cross talk between cell death and inﬂammation in breast cancer cells. The expression
of MITA was signiﬁcantly lower on in estrogen receptor (ER) positive breast cancer cells than ER negative cells.
Similarly, it was signiﬁcantly down regulated in tumor tissue as compared to the normal tissue. The overexpres-
sion of MITA in MCF-7 and T47D decreases the cell proliferation and increases the cell death by activation of
caspases. MITA positively regulates NF-κB transcription factor, which is essential for MITA induced cell death.
The activation of NF-κB induces TNF-α productionwhich further sensitizesMITA induced cell death by activation
of death receptor pathway through capsase-8. MITA expression decreases the colony forming units and migra-
tion ability of MCF-7 cells. Thus, our ﬁnding suggests that MITA acts as a tumor suppressor which is down regu-
lated during tumorigenesis providing survival advantage to tumor cell.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Breast cancer is the secondmost common formof cancerworldwide.
About 1.3 million women are diagnosed with breast cancer annually
and more than 400,000 women die from the disease around the world
[1,2]. In spite of extensive efforts, there is signiﬁcantmorbidity andmor-
tality associated; therefore, understanding the pathogenesis of breast
cancer is of immense importance.
Evidences support the view that chronic inﬂammation contributes
to initiation and progression of cancer [3–5]. The patients with ulcera-
tive colitis and Crohn's disease are at increased risk for developing
colorectal cancer. Similarly, inﬂammation and infection of liver are
associated with increased risk of hepatic cancer [6,7]. The experimental
evidences demonstrating association of inﬂammation and breast
cancer are emerging. Chronic inﬂammation plays a critical role in breast
cancer occurrence/recurrence [8]. Inﬂammatory Breast Cancer (IBC) is
one of the most aggressive types of breast cancer. The symptoms of
IBC like swelling, skin redness, and an orange peel like texture of the
skin are similar to inﬂammation. IBC is often misdiagnosed as mastitisemistry, Faculty of Science,
Gujarat, India. Tel.: +91 265
ights reserved.and even antibiotics are prescribed to the patients [9]. These observa-
tions suggest that there is a strong linkage between inﬂammation and
breast cancer. The biochemical mechanisms regulating inﬂammation in
breast tissue and their associationwith breast cancer are not understood.
NF-κB and IFNs are important cellular pathways associating inﬂam-
mation and cancer. The regulation of NF-κB and IFN pathways is exten-
sively studied; however, its modulation in stimulus speciﬁcmanner and
its signiﬁcance to tumorigenesis are still not clear. Recent studies
suggest that sub-cellular organelles, speciﬁcally mitochondria and ER,
provide novel signaling platform for the assembly of signalosomes.
Mitochondria are emerging as a central regulator of viruses and bacteria
induced inﬂammatory pathways. The discovery of mitochondria associ-
ated viral signaling protein (MAVS) on the outer membrane of mito-
chondria and its role in regulating NF-κB and IFN pathway during viral
and bacterial infections suggested a strong linkage between mitochon-
dria and inﬂammation [10]. Similarly, ER associated protein MITA is
another link that might help understand the linkage between ER, mito-
chondria and inﬂammation.
MITA plays an important role in inﬂammation through regulation of
NF-κB and IFN [11]. MITA interacts with RIG-I, and MAVS associated
signalosome. This further activates downstream kinase complexes: the
‘non-canonical’ IKK-related kinase TBK1 or IKK complex [12]. The
TBK1 complex induces the phosphorylation and dimerization of the
transcription factors (IRF3 and IRF7), which translocate to the nucleus
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ing type I IFN genes and downstream IFN-inducible genes [13]. On the
other hand IKK complex activates NF-κB, subsequently promoting the
expression of pro-inﬂammatory cytokines and other cell survival/
death genes.
Given the strong linkages of inﬂammation and cancer, we hypothe-
size that MITA may be critical regulator of either cell survival or cell
death, however, evidences are still lacking. We studied the expression
of MITA in tumorous tissues of human breast cancer patients as well
as in different breast cancer cell lines and investigated its role as a
potential tumor suppressor. We observed that expression of MITA is
predominant in extra-tumoral tissue whereas lower in tumorous tissue.
MITA sensitizes the breast cancer cells to TNF-α induced cell death.
MITA induced NF-κB is essential for cell death as well as clonogenic
ability of the cells.
2. Materials and methods
2.1. Cells and cell culture
MCF7, T47D and HBL100 breast cancer cell lines were obtained from
National Center for Cell Sciences, Pune, India.MDA-MB-231was a gift of
Prof. R. P. Singh (Central University of Gujarat, India). MCF-7, ZR-75-1
and T47D cells were cultured in RPMI 1640 (Life Technologies, USA),
HBL100 in Dulbecco's modiﬁed Eagle's medium (Life Technologies,
USA) and MDA-MB-231 in Leibovitz's L-15 media (HI-MEDIA, India).
The media used were supplemented with 10% FBS (Life Technologies,
USA) and 1% penicillin, streptomycin, and neomycin (PSN) antibiotic
mixture (Life Technologies, USA). Cells were incubated at 37 °C, 5%
CO2 in speciﬁed media. MCF 10A cells were cultured in DMEM F12
(INVITROGEN) base media supplemented with (10% horse serum)
along with the following supplements: 1) cholera toxin (100 ng/ml),
2) EGF (20 ng/ml), 3) hydrocortisone (500 ng/ml), and 4) insulin (cell
culture tested) (10 μg/ml).
2.2. Plasmids and reagents
MITA cloned in pCMV6-ENTRYplasmidwas a gift fromDr. Hong-Bing
Su (Wuhan University, China). p65shRNA (RelA1 shRNA and RelA2
shRNA) and control shRNA were provided by Dr. Edurne Berra Ramírez
(Gene Silencing Platform, CICbioGUNE, Derio, Spain). MITA shRNA was
a generous gift by Dr. Peter Chumakov (Engelhardt Institute ofMolecular
Biology, Russian Academy of Sciences). FDEVDG2 construct was gifted by
Dr. Brian Seed (Department of Genetics, Harvard Medical School,
Cambridge Street, Boston). Primary antibodies used were MITA
(Proteintech, USA), caspase-8, PARP, p65 (Cell Signaling Technology,
Inc., USA), β-Actin and GAPDH (Abcam, USA), IκBα (Cell Signaling Tech-
nology, Inc., USA). HRP-conjugated anti-rabbit and anti-mouse antibod-
ies (Thermo Scientiﬁc, USA) were used. The reagents used were TNF-α
(Tumor necrosis factor) (Biovision, USA), PDTC (Pyrrolidine dithiocarba-
mate) (Sigma Aldrich, USA) zVAD-fmk (N-Benzyloxycarbonyl-Val-Ala-
Asp(O-Me) ﬂuoromethyl ketone) (Biovision, USA), IETD-fmk (Ile-
Glu(OMe)-Thr-Asp(OMe)-ﬂuoromethyl ketone) (Clontech, USA).
2.3. Transfection
MCF-7 cells were transfected using standard calcium phosphate
method [14]. MCF-7 cells and T47D were transfected using X-treme
gene transfect reagent (Roche, Germany). HBL100 cells were transfected
with X-tremeGENE 9 DNA transfection reagent (Roche, Germany) as per
manufacturer's protocol.
2.4. Collection of tissues
Human breast tumor specimenswere obtained frompatients under-
going surgery. Tissues were collected from the tumor zone (tissuewithin the tumor boundary), and normal zone (distal normal tissue at
least 10 mm from the outer tumor boundary). A fraction of all tissues
was ﬁxed in formalin and embedded in parafﬁn for routine histopatho-
logical analysis. The rest of the fractions were frozen in liquid nitrogen
and then stored at−80 °C for RNA and protein extraction. Ethical ap-
proval from institute's ethical committee was taken prior to collection
of sample for each of the patients. Details of the tissue specimen used
are given in Supplementary Table 1.
2.5. Immunohistochemistry
After de-parafﬁnization in xylene and hydration by gradient alcohol
series, antigen retrieval was done by heat treatment in citrate buffer
(10 mM, pH 6.0). The sections were incubated in 10% NSS (normal
sheep serum) for 20 min to block non-speciﬁc binding and further incu-
bated with antibodies against MITA (1:1000) in 0.1% BSA overnight at
4 °C. Sections were stained using Quick Universal ABC KIT (Vector)
followed by peroxidase staining reactionwith DAB/H2O2 as chromogen.
The stained sections were observed under bright ﬁeld light microscope
(Nikon Eclipse 80i; Nikon Instech Co. Ltd., Kawasaki, Kanagawa).
2.6. Quantitative analysis of gene expression
Total RNA was isolated using Tri Reagent (Life technologies, USA)
and was reverse transcribed to synthesize cDNA using Transcriptor
First Strand cDNA synthesis kit (Roche, Germany) or SuperScript VILO
cDNA Synthesis Kit (Life technologies, USA) according to the
manufacturer's instructions. Real time PCR was performed using SYBR
Premix Ex TaqTM (Takara, Japan) or SYBR mix (life technologies, USA)
or Applied Biosystems as per manufacturer's instructions.
Speciﬁc primers of the genes are listed below.
1. MITA: Fwd 5′-CGCCTCATTGCCTACCAG-3′;
Rev, 5′-ACATCGTGGAGGTACTGGG-3′;
2. TNF-α: Fwd 5′-CCCAGGGACCTCTCTCTAATCA-3′;
Rev 5′-GCTACAGGCTTGTCACTCGG-3′;
3. β-Actin: Fwd 5′-TCGTGCGTGACATTAAGGGG-3′;
Rev 5′-GTACTTGCGCTCAGGAGGAG-3′;
4. 16s rRNA: Fwd 5′-GAAACCAGACGAGCTACCTAAG-3′;
Rev 5′-GCCTCTACCTATAAATCTTCCC-3′;
5. GAPDH: Fwd 5′-AGAAGGCTGGGGCTCATTTG-3′;
Rev 5′AGGGGCCATCCACAGTCTTC 3′.
2.7. Western blot
Cells were plated at a density of 4.5 × 105 cells/well in the six well
plate and transfected with indicated expression plasmid or shRNAs
using calcium phosphate method. After 48 h of transfection, the cells
were harvested, washed with ice cold PBS and lysed in buffer A
(150 mMNaCl, 30 mM Tris–Cl, 10% Triton X-100, 10% Glycerol, 1× Pro-
tease Inhibitor (Roche, Germany). The equal protein was loaded and re-
solved on 11% SDS-PAGE. Protein was electroblotted on PVDF
membrane at 110 V for 1 h at 4 °C. The membrane was blocked with
5% blocking buffer (5% non-fat dried milk and 0.1% Tween-20 in TBS)
or 5% BSA (BSA (Sigma-Aldrich, USA), 0.1% Tween-20 in TBS-0.02 M
Tris–Cl, 0.15 M NaCl) for 1 h at room temperature. The membrane
was incubated overnight with speciﬁc primary antibody. After incuba-
tion, the membrane was washed three times with TBS-T (TBS contain-
ing 0.1% Tween-20) for 10 min and incubated with a secondary
antibody at room temperature for 1 h. The membrane was washed
three times with TBS-T and signal was visualized by using EZ-ECL
chemiluminescence detection kit for HRP (Biological Industries, Israel)
by exposing it to X-ray ﬁlm.
For the western blotting from tissue samples, the tissue samples
obtained from breast cancer patientwere snap frozen in liquid nitrogen.
The tissue was homogenized to ﬁne powder in the presence of liquid
Fig. 1.Analysis of expression ofMITA in breast cancer cell lines and different tumor tissue of breast cancer patient: (A) RNAwas isolated fromMCF7, T47D, HBL100 andMDAMB231 breast
cancer cell lines, cDNA prepared and quantitative expression ofMITAwas analyzed using qPCR. (B) Protein level expression ofMITA in different breast cancer cell lineswas analyzed using
western blot analysis using antibody against MITA. (C) RNAwas isolated from tumorous and extra-tumoral tissues of breast cancer patients and relative expression ofMITAwas analyzed
using qPCR. (D) Protein level expression of MITA was analyzed in the tumoral and extra tumoral tissue by western blot analysis using antibody against MITA. (E) Immunohistochemical
analysis of tumoral and extra-tumoral tissues was done by incubating the tissue sections with antibody against MITA and detected using DAB staining.
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NaCl, 5 mM EDTA, 1 mM EGTA, 0.1% SDS, and 1% Triton X-100, 0.2%
protease inhibitor cocktail, 1 mMPMSF, 2 mMNaF and 2.5 mM sodium
pyrophosphate). The lysates were freeze thawed three times in liquid
nitrogen. After 15 min of centrifugation (4000 rpm at 4 °C), the super-
natantwas saved to use as awhole-cell lysate. The proteinwas analyzed
by western blotting as described above.
2.8. NF-κB luciferase assay
To assess NF-κB activity, MCF-7 cells were plated at density of
1 × 105 cells/well in 24 well plate and luciferase assay was performed
as described previously using Dual-Glo luciferase assay system
(Promega, USA) [15].
2.9. Caspase 3/7 and caspase-8 activity assay
The activity was performed using Caspase-GloR 3/7 Assay kit
(Promega, USA) or Caspase-GloR 8 Assay kit (Promega, USA). Cells
were plated at the density of 4 × 104 cells per well in 96 well whiteclear bottom plate and transfected with indicated expression plasmids
or shRNAs and respective controls. Caspase-GloR 3/7 (10 μl) reagent or
caspase-8 Glo reagent was added to each well and luminescence was
measured with a Centro LB 960 Luminometer (Berthold Technologies,
Germany).
2.10. Secreted GLUC activity assay for caspase activation in
culture supernatant
Cells were plated in 24 well plate and co-transfected withMITA and
a reporter construct FDEVDG2 [16]. The construct has a DEVD site
placed in between GLUC reporter (Gaussia luciferase) and β-actin, so
once the substrate site is cleaved by the caspases, luciferase will be
secreted in the supernatant. After 24 h of transfection, the cells were
treated with speciﬁc inducer of cell death. The supernatant (SN) was
collected and centrifuged at 14,000 rpm for 5 min. Supernatant was
diluted in 1:10 in 100 μl 1× lysis buffer. The substrate was added.
50 μl of substrate was added to 10 μl of this mixture and was analyzed
with Centro LB 960 Luminometer (Berthold Technologies, Germany).
Attached cells were lysed in 1× lysis buffer 100 μl per well for 15 min.
Fig. 2.MITA induces cell death: The speciﬁed cells were transfected with MITA and cell
survival was monitored using (A and B) MTT reduction assay. Cell death was measured
in MCF-7 cells by (C) trypan blue exclusion assay and (D) PARP cleavage.
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GLUC activity luminescence was measured with a Luminometer. Total
caspase activity was calculated in the SN as well as in cell lysate, and
total caspase activity was calculated as the ratio of the caspase activity
in SN versus (vs) cellular caspase activity.2.11. Trypan blue exclusion assay
Cells were plated at the density of 1 × 105 cells/well in 24well plate
and transfected with the speciﬁc constructs. After 24 h of transfection,
the cells were treated with TNF-α (10 ng/ml) for 24 h and stained
with trypan blue. Minimum 100 cells per view were counted and
percentage of cell survival was plotted.2.12. MTT assay
The cellular proliferation was analyzed by MTT assay. MCF7 cells
were plated in 24-well plate at a density of 1 × 105 cells/well. The
cells were transfected with MITA as well as vector. After 24 h of trans-
fection, 20 μl of MTT solution (5 mg/ml) (Serva, Germany) was added
to eachwell and incubated for 2 h. After incubation, 500 μl of solubiliza-
tion buffer (2% w/v SDS, 18.5% w/v formaldehyde) was added to
dissolve the precipitate of purple colored formazan and color intensity
was monitored using colorimetric microplate reader (BioTek Instru-
ments, Inc. USA) at 595 nm wavelength.2.13. Colony formation assay and scratch assay
Clonogenic activity of cells and migration ability of cells were deter-
mined as described previously [15,17].2.14. Statistical analysis
Data are shown as mean ± SEM for no. of times experiment was
repeated. Comparisons of groups were performed using student t-test
for repeated measurements to determine the levels of signiﬁcance for
each group. The experiments were performed minimum two times
independently and p b 0.05 was considered as statistically signiﬁcant.
GraphPad Prism was used to perform all the statistical analysis.
3. Results
3.1. Expression analysis of MITA in different breast cancer cell lines and
patient samples
To study the role of MITA in initiation and progression of breast
cancer, we analyzed the expression of MITA in different breast cancer
cell lines. Relative expression of MITA in four different breast cancer
cell lines (MCF-7, T47-D, HBL100 and MDA-MB-231) was analyzed by
quantitative Real Time PCR. The expression of MITA was signiﬁcantly
lower in MCF-7 and T47-D cell lines as compared to HBL100 and
MDA-MB-231 cells (Fig. 1A). The protein levels of MITA were checked
in the same set of cell lines as well as in MCF-10A (non-tumorigenic
mammary epithelial cells) and ZR-75-1 (ER-positive) cell lines by
western blotting. The intense band of 40 kDa band corresponding to
MITA was observed in HBL-100 indicating the strong expression of
MITA. Similarly the non-tumorigenic cell line MCF-10A showed high
level of MITA expression (Fig. 1B). The lower level of MITA was also ob-
served in MDA-MB-231 as compared to HBL100 whereas it remained
undetected in MCF7 and T47D (Fig. 1B). Similarly, ER positive cell line
ZR-75-1 showed low level expression of MITA.
ExpressionofMITAwas further investigated in tumor tissues obtained
from breast cancer patients using quantitative real time PCR. Interesting-
ly, signiﬁcantly low RNA levels of MITA were observed in all tumorous
tissues as compared to the extra-tumoral tissue (Fig. 1C). Similarly,
protein levels of MITA were also low in all tumorous tissue as compared
to the extra-tumoral tissue of the same patient (Fig. 1D). The expression
of MITA was also analyzed by immunohistochemistry. Intense staining
of MITA observed in case of extra-tumoral tissue as compared to tumor-
ous tissue conﬁrmed our observations (Fig. 1E). These evidences suggest
that MITA is primarily expressed at higher levels in extra-tumoral tissue
and pre-malignant cell lines, whereas, it decreases signiﬁcantly in tumor-
ous tissue and malignant breast cancer cell lines.
3.2. MITA induces cell death in breast cancer cell lines
As the expression of MITA decreased in tumorous tissue from breast
cancer patient as well as in malignant cell lines, we hypothesized that
MITA may be a potential tumor suppressor either by regulating cell
survival or cell death. MCF-7 cell line having relatively low expression
of MITA was chosen for further experiments. MITA was overexpressed
in MCF-7 and cell proliferation wasmonitored usingMTT. The transfec-
tion of MITA in MCF-7 showed decreased cell survival as compared to
vector transfected cells (Fig. 2A). To eliminate the cell line speciﬁc
action, T47D cells were transfected with MITA and cell survival was
monitored. Decrease in MTT reduction was observed in case of MITA
expressing cells as compared to control indicating decrease in the cell
survival (Fig. 2B).
To further conﬁrm if MITA induced decreased proliferation is due to
cell death, the effect of MITA expression on induction of cell death was
analyzed by trypan blue exclusion assay. The expression of MITA in
MCF-7 signiﬁcantly decreased trypan blue negative cells as compared
to control cells, indicating increased cell death (Fig. 2C). Themechanism
of cell death was further investigated. PARP is an established marker of
apoptosis as it is a target of executioner caspases and is cleaved during
apoptosis [18,19]. MCF-7 cells were transfected with MITA and PARP
cleavage wasmonitored after 24 h of transfection. The western blotting
Fig. 3.MITA induces caspase activation during cell death: (A and B) The speciﬁed cells were transfectedwithMITA and caspase activitywasmeasured using caspase glo substrate followed
by luminescencemeasurement. (C) HBL100 cells were transfectedwithMITA shRNA alongwith the FDEVDG2 construct and the luminescencewasmeasured in the SN and the cell lysate.
Total caspase activity was calculated as the ratio of caspase activity in the SN vs cell lysate. (D and E) Caspases were inhibited inMITA transfected cells using PAN caspase inhibitor zVAD-
fmk (20 μM) for 24 h. (D) Cell death was monitored using trypan blue exclusion assay and (E) caspase activity was measured using caspase glo substrate.
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form respectively. The expression of MITA showed increased levels of
cleaved PARP (89 kDa) as compared to control (Fig. 2D).
The cleavage of PARP strongly suggests the activation of caspases in
the presence ofMITA. Caspases play amajor role in initiation and execu-
tion of cell death; hence caspase 3/7 activationwas analyzed using lucif-
erase assay. The expression of MITA in MCF-7 signiﬁcantly increased
luminescence indicating enhanced caspase3/7 activity (Fig. 3A). The
caspase activity was also monitored in T47D cell line in the presence
of MITA and similar results were observed (Fig. 3B). As MITA was
observed at higher level in ER negative HBL100 cells, MITAwas knocked
down in these cells to further conﬁrm the role of MITA in cell death. The
total caspase activity was monitored in HBL100 cell line using Gluc
reporter based luciferase assay system in the MITA knocked down
condition. The basal caspase activity decreased signiﬁcantly upon
MITA knocked down in HBL100 cells (Fig. 3C). The result further
strengthened our hypothesis that MITA induces cell death by activatingcaspases. The role of caspases in cell death was further validated by
inhibiting caspases using pan caspase inhibitor zVAD-fmk and then
monitoring the cell death. The treatment of MITA transfected MCF-7
cells by zVAD-fmk signiﬁcantly increased trypan blue negative cells as
compared to control (Fig. 3D). Caspase activity was monitored by lucif-
erase assay to conﬁrm the inhibition of caspases. Decrease in caspase
activities was observed in the cells treated with zVAD-fmk (Fig. 3E).
These observations strongly suggest that inhibition of caspases rescues
MITA induced cell death.
3.3. MITA regulates cell death by inducing NF-κB
NF-κB is a key regulator of pro- and anti-apoptotic genes during cell
death. MITA is a key regulator of central inﬂammatory pathway [11],
hence the role of NF-κB was analyzed in MITA induced cell death.
MITA was co-transfected with NF-κB luciferase reporter construct in
MCF-7 cells and luciferase activity was measured. The signiﬁcant
Fig. 4.MITA activates NF-κB transcription factor: (A) MITA was transfected inMCF-7 cells
and NF-κB activity was measured using luciferase assay system. The activity was normal-
ized and represented as Fireﬂy/Renilla ratio. (B) MITA was transfected in MCF-7 cells and
the level of p65 was analyzed by western blot using anti-p65 antibody. (C) Nuclear frac-
tion and cytosolic fraction of MITA transfected cells were subjected to western blot analy-
sis using p65 speciﬁc antibody.
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compared to control indicating activation of NF-κB by MITA (Fig. 4A).
The activated form of NF-κB is a heterodimer consisting of a p50 subunit
and p65, and the expression of p65 is positively regulated by NF-κB [20].
Thereforewe analyzed the expression of p65 in the presence ofMITA by
westernblotting. Elevated level of p65was observed inMITA expressing
cells as compared to control (Fig. 4B). During NF-κB activation, p65/p50
translocates to the nucleus to execute its action. Therefore the transloca-
tion of NF-κB to the nucleus was analyzed by sub-cellular fractionation
of MITA transfected cells along with the control. TNF-α was taken as a
positive stimulus. We observed increase in the level of p65 in nuclear
fraction ofMITA transfected cells as compared to the vector in untreated
as well as TNF condition (Fig. 4C). IKK complex is the central kinase
complex during NF-κB activation [20]. Hence, to further understand
the mechanism of NF-κB activation through MITA, components of IKK
complex (IKKα, IKKβ, IKKγ) were knocked down using respective
shRNAs in MITA transfected MCF-7 cells and NF-κB activity was mea-
sured using luminescence. p65, the most downstream component of
NF-κB pathwaywas also knocked down using speciﬁc shRNA to analyze
ifMITA acts downstreamof IKK complex. NF-κB activitywas signiﬁcant-
ly suppressed upon any of the three components of IKK complex ana-
lyzed (Supplementary Fig. 1). The experimental evidences strongly
suggest that MITA acts at IKK complex and activates NF-κB.
To understand the role of NF-κB activation in MITA induced cell
death, NF-κB activation was inhibited using p65 shRNA as well as
chemical inhibitor PDTC and cell death was monitored using trypan
blue exclusion assay. The knockdown of p65 in MCF-7 signiﬁcantly
increased trypan blue negative cells in the presence of MITA as com-
pared to control (Fig. 5A). Similar results were observed in case of
chemical inhibition of NF-κB in MITA transfected cells (Fig. 5B). These
evidences suggest that NF-κB activation is essential for cell death. We
also conﬁrmed the role of NF-κB in caspase activation by luciferase
assay system. Increased caspase activity was observed in the presence
of MITA; whereas knockdown of p65 using shRNA reverted back tothe control (Fig. 5C). Similarly, the expression of MITA in MCF-7 cells
treated with PDTC also showed no increase in caspase activity as com-
pared to control (Fig. 5D). PARP cleavage was also monitored in similar
conditions. The transfection of MITA showed increased levels of cleaved
PARP (89 kDa) as compared to control. The knockdown of p65 in the
presence of MITA showed decreased level of cleaved PARP as compared
to control (Fig. 5E). These results convincingly demonstrate that MITA
induced NF-κB is essential for the induction of cell death.
3.4. NF-κB regulates cell death by increasing TNF-α production
To further investigate the role of NF-κB in the regulation of MITA
induced cell death, the expression of NF-κB regulated genes (BCL-XL,
BCL-2, Bax, TNF-α, cΙΑP1, cIAP2 and XIAP) was screened in MITA
transfected cells using quantitative PCR. Elevated expression of TNF-α
was observed in the cells expressing MITA as compared to control
(Fig. 6A); however no signiﬁcant differencewas observed in the expres-
sion of other genes (data not shown). The role of increased TNF-α and
its contribution in regulation of MITA induced apoptosis were further
investigated. MITA transfected cells were treated with TNF-α for 24 h
and cell death was monitored. Signiﬁcant decrease in the percentage
of trypan blue negative cells was observed in TNF-α treated cells as
compared to untreated cells in the presence of MITA indicating sensiti-
zation of MITA induced cell death by TNF-α (Fig. 6B).
Caspase-8 is a key player of TNF induced cell death therefore it was
hypothesized earlier that caspase-8 activationmay be an important reg-
ulator of cell death induced by MITA [21]. MCF-7 cells were transfected
with MITA and caspase activation was monitored by western blotting.
An intense band of 43/41 kDa corresponding to cleaved caspase-8 was
clearly observed in MITA transfected cells as compared to control
(Fig. 6C). To further conﬁrm the role of caspase-8 in MITA induced cell
death, caspase-8 was inhibited using a speciﬁc inhibitor IETD-fmk and
cell deathwasmonitored. Inhibition of caspase-8 increased the number
of trypan blue negative cells in MITA expressing cells as compared to
control (Fig. 6D). HBL100 cells showed high expression of MITA;
hence we monitored the effect of knockdown of MITA on caspase-8
activity. The knockdown of MITA in HBL100 showed decreased
caspase-8 activity (Fig. 6E). This indicates that caspase-8 plays a key
role in MITA induced cell death. The above results showed that MITA
expression activates NF-κB and induces the expression of TNF and that
may initiate death receptor pathway. To conﬁrm this p65was downreg-
ulated by p65 shRNA in MCF-7 cells in the presence of MITA and
caspase-8 activity was monitored. The caspase-8 activity was observed
to be equivalent to control which was otherwise increased in case of
MITA transfectedMCF-7 cells (Fig. 6F). These evidences strongly suggest
that endogenous expression ofMITAmay sensitize breast cancer cells to
TNF induced cell death and its loss in tumor cells provided survival
advantage.
3.5. MITA decreases clonogenic ability of MCF-7 cells
The experimental evidences in the current study showed that MITA
is expressed at lower levels in breast tumor than normal cells. It also
sensitizes MCF-7 to cell death. Therefore we hypothesized that it may
be a potential tumor suppressor. This observation was conﬁrmed by
monitoring the clonogenic ability of the MFC-7 cells in the presence of
MITA. The expression of MITA in MCF-7 cells signiﬁcantly decreased
colony forming units as compared to control (Fig. 7A). As we observed
here that MITA induced NF-κB is responsible for cell death, the role of
NF-κB in MITA induced reduction in clonogenic ability of the cells was
also analyzed. MCF-7 cells were transfected with MITA along with
control and p65 shRNA and clonogenic ability of the cells was moni-
tored. The clonogenic ability of the cells signiﬁcantly increased upon
p65 knockdown in the presence of MITA as compared to control
(Fig. 7B). These evidences strongly suggest that MITA decreases the
clonogenic ability of MCF-7 cells by positively regulating NF-κB. We
Fig. 5.MITA induced NF-κB is essential for cell death: MITA was transfected in MCF7 cells and NF-κB was inhibited using p65 shRNA or chemical inhibitor PDTC (100 μM) and cell death
was quantiﬁed by (A and B) trypan blue exclusion assay. Caspase activity (C and D) and PARP cleavage were (E) also monitored in similar experimental conditions.
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transfected withMITA andmigration ability was analyzed using scratch
assay. There was a signiﬁcant increase in the open wound area of MITA
transfected cells observed as compared to the control (Fig. 7C). To fur-
ther conﬁrm the role of MITA on migration ability of breast cancer
cells, MITA was knocked down in HBL100 cells and its migration ability
was monitored. There was a signiﬁcant decrease observed in HBL100
cells upon MITA knock down (Fig. 7D). These observations strongly
suggest that MITA regulated NF-kB negatively regulates clonogenic
and migration ability of the breast cancer cells.
4. Discussion
The relation between inﬂammation and breast cancer is an emerging
area. The current study is focused on ER resident MITA which is known
to be essential for innate immune response against dsDNA virus and
regulate both IFN and NF-κB pathway [11,22,23]. It has been observed
that circulating tumor DNA levels increase in body ﬂuids in different
cancers including breast cancer [24–26]. Interestingly it had been
observed that tumor DNA in complex with endogenous antimicrobial
peptide LL37 can be transported back into endosomal compartmentsof plasmacytoid dendritic cells (pDC) leading to activation of type I
IFNs [27]. It is possible that dsDNA induced pathway regulated by
MITA may be linked to breast tumorigenesis which has not been inves-
tigated. In the current study, we demonstrated that MITA may be a
potential tumor suppressor regulating NF-κB induced cell death in
breast cancer.
The evidences in the current study suggest that expression of MITA
is down regulated in tumor tissue as compared to normal. MITA is highly
expressed in non-tumorigenic MCF10A cells whereas it is expressed at
low levels in ER positive cells MCF-7, T47D and ZR-75-1. These ﬁndings
suggest that during breast cancer progression, ER positive tumors specif-
ically down regulate the proteins involved in innate immune response
suggesting the evolved mechanisms to evade innate immune response
pathways to facilitate tumor growth. This is further supported by loss
of expression of RIG1, intracellular sensor of dsRNA, in ER positive cell
lines [28]. It would be interesting to further study the correlation be-
tween the ER status and expression of MITA and other proteins involved
in innate immune response and relevance during breast tumorigenesis.
The evidences in the current study clearly showed thatMITA expres-
sion leads to cell death in breast cancer cell lines. The down regulation of
MITA in tumor tissue and ER positive cell lines strongly suggests that it
Fig. 6.MITA induced NF-κB sensitizes MCF-7 to TNF induced cell death: (A) MCF-7 cells were transfected with MITA. RNA was isolated and reverse transcribed to prepare cDNA. Relative
mRNA level of TNF-αwasquantiﬁedusing real time PCR. (B)MITA transfected cellswere treatedwith 10 ng/ml of TNF-α for 24 h and cell deathwasmeasuredusing trypanblue exclusion
assay. (C) MCF-7 cells were transfected with MITA and caspase-8 activity was analyzed by using western blotting. (D) Caspase-8 activity was inhibited using IETD-fmk (1 μM) and cell
death was monitored using trypan blue exclusion assay. (E) HBL100 cells were transfected with MITA shRNA and control random shRNA and caspase-8 activity was measured using
caspase-8 glo substrate followed by luminescence measurement. (F) MITAwas transfected inMCF7 cells and NF-κB was inhibited using p65 shRNA and caspase-8 activity was measured
using luminescence.
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matory and cell death pathway. As mentioned earlier, MITA is a critical
regulator of NF-κB and IFN. These pathways are important cellular
pathways associating inﬂammation and cancer [29,30]. The evidences
here clearly demonstrated that MITA up regulates NF-κB pathway
through IKK complex. Increased NF-κB activity has been found in both
ER positive and ER negative breast cancer patients. The dysregulation
of NF-κB and its implication to the breast cancer or any other cancer
may be dependent on either loss or ampliﬁcation of tumor suppressor
or oncogene. The decreased expression of MITA and increased NF-κB
activity provide advantage to the tumor cells. The association of NF-κB
and breast cancer is further emphasized by recent observation of ampli-
ﬁcation of IKKε, a kinase regulating NF-κB pathway, in tumor tissue of
breast cancer patients and breast cancer cell lines [31]. The gene is
over expressed in over 30% of the breast carcinomas and provides
survival advantage to tumor cells [31,32].NF-κB is a dynamic transcription factor that induces the expression
of several pro-apoptotic and anti-apoptotic genes. The role of NF-κB
has been controversial as it may have pro-survival or apoptotic effect
depending upon the stimulus and loss/gain of potential tumor suppres-
sor/oncogene [33,34]. The current study also showed thatMITA induced
up regulation of NF-κB leads to high levels of TNF-α in breast cancer
cells. Interestingly, TNF-α treatment further sensitized breast cancer
cells to MITA induced cell death. TNF-α is known to bind to its receptor
TNFR-I/II, either leading to NF-κB activation or cell death [35]. The p65
knockdown decreases the caspase-8 activity in MITA overexpressed
conditions. The study strongly suggests that MITA induced NF-kB and
increased level of TNF-α in breast cancer cells (MCF-7) lead to the acti-
vation of caspase-8 and downstream proteolytic cascade leading to cell
death. The current study suggests that TNF-α shows antitumoric effect
in the presence of MITA among its ability to play diverse role as pro or
antitumoric agent. TNF in combination with melphalan is strongly
Fig. 7. The expression of MITA decreases clonogenic ability of MCF7 cells: (A) The cells were transfected with MITA and control vector or (B) co-transfected with p65shRNA or control
random shRNA and clonogenic ability was analyzed as described in Materials and methods section. The colonies were stained with crystal violet for the assessment of clonogenic ability.
(C) MITA was transfected in MCF-7 cells and migration ability of MCF-7 cells was checked by scratch assay as described in Materials and methods section. (D) MITA shRNA and control
random shRNA were transfected in HBL100 cells and its migration ability was checked by scratch assay.
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it has been shown that TNF-α expressing MDA-MB231 cells failed to
form tumor in vivo. It also suggests that TNF-α interrupts symbiotic
metabolic coupling between epithelial cancer cells and their host stro-
mal microenvironment leading to death [37]. MITA down regulation
in breast cancer tissue is a strategy of tumor to resist the antitumor
effect of TNF-α.
The activation of cell death pathway strongly suggests that expres-
sion of MITA leads to decrease in the clonogenic ability. The migration
ability of MCF-7 as well as HBL100 cells is also affected in the presence
or absence of MITA respectively. The activation of caspase-8 is known
to negatively regulate migration ability of the cells [38,39]. Caspase-8
binds to the lamella of the migrating cell and promotes the cell migra-
tion. Its catalytic activity is not required for the process. The decreasedmigration of MCF-7 cells upon MITA expression might be due to the
increase in caspse-8 activity which ultimately makes pro-caspase-8
unavailable for binding and thus migration. Unraveling the mechanism
of role of MITA in connecting these two observations is important to
modulate the innate immune pathway for therapeutic intervention in
breast cancer.
5. Conclusion
The current study provides strong evidences that MITA can act as
potent tumor suppressor. MITA is signiﬁcantly down regulated in breast
cancer patients as well as in ER positive breast cancer cell line. The
evidences in the current study suggest that MITA might prove to be an
essential link to inﬂammation, endoplasmic reticulum and cancer. This
153K. Bhatelia et al. / Biochimica et Biophysica Acta 1842 (2014) 144–153hypothesis clearly warrants further study to understand link between
inﬂammation and breast cancer.
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